Completed NA INTERVENTIONAL 2-arm NCT01261364

Pharmacogenetic-Directed Treatment for Major Depression

The Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting:A Randomized Double Blind Pilot Study

Sponsor: Assurex Health Inc.

Conditions Depression

Interventions GeneSightRx Treatment as usual

Updated 5 times since 2017 Last updated: Dec 2, 2015 Started: Sep 30, 2009 Primary completion: Jan 31, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01261364, this NA trial focuses on Depression and remains completed. Sponsored by Assurex Health Inc., it has been updated 5 times since 2009, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assurex Health Inc.
Pine Rest Christian Mental Health Services

Data source: Assurex Health Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.